FDA notifications. Abacavir package insert changes approved. Hypersensitivity, other issues addressed.
D015224:Dideoxynucleosides / Q000009:adverse effects*; D004342:Drug Hypersensitivity; D004348:Drug Labeling; D006801:Humans; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects*; D014481:United States; D014486:United States Food and Drug Administration; D000099227:Abacavir
D015224:Dideoxynucleosides; D018894:Reverse Transcriptase Inhibitors; D000099227:Abacavir